Sep 30, 2021

Semler Scientific Q3 2021 Earnings Report

Semler Scientific's Q3 2021 financial performance reflected a revenue increase compared to the same period last year, but net income decreased.

Key Takeaways

Semler Scientific reported a 30% increase in revenue for Q3 2021 compared to Q3 2020, reaching $14.0 million. However, net income decreased by 15% to $4.2 million, and diluted EPS decreased to $0.51.

Revenue increased by 30% compared to the same quarter last year.

Net income decreased by 15% compared to the same quarter last year.

Cost of revenues increased to 10% of revenues, compared to 8% in the prior year.

Cash and cash equivalents increased to $35.9 million.

Total Revenue
$14M
Previous year: $10.7M
+30.4%
EPS
$0.51
Previous year: $0.61
-16.4%
Gross Profit
$12.6M
Previous year: $9.91M
+27.3%
Cash and Equivalents
$35.9M
Previous year: $16.8M
+114.0%
Free Cash Flow
$7.61M
Previous year: $3.52M
+116.6%
Total Assets
$51M
Previous year: $28M
+81.7%

Semler Scientific

Semler Scientific

Forward Guidance

Semler Scientific expects continued profitability and generation of cash from operating activities for the remainder of 2021 and in 2022. The company intends to grow annual revenues at a faster rate than annual expenses and to remain profitable.

Positive Outlook

  • Continued profitability expected
  • Generation of cash from operating activities expected
  • Intent to grow annual revenues at a faster rate than annual expenses
  • Aim to remain profitable
  • Focus on expanding product offerings

Challenges Ahead

  • Uncertainty created by COVID-19
  • Risk of insurance plans discontinuing licenses
  • Risk of customers discontinuing licenses
  • Potential inability to expand product offerings successfully
  • Potential inability to control expenses and preserve cash